(Q35615210)

9 August 2017

1 reference

title

Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder (English)

1 reference

transitional cell carcinoma

9 August 2017

1 reference

1 reference

Derek Raghavan

1

1 reference

9 August 2017

publication date

1 November 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

21

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

468-474

1 reference

Biology and management of bladder cancer

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Elevated Expression of P-Glycoprotein in Kidney and Urinary Bladder Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

p53 and treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Natural history of surgically treated bladder carcinoma with extravesical tumor extension.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Southwest Oncology Group studies in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Overview of bladder cancer trials in the European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Overview of bladder cancer trials in the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

Molecular targeting and pharmacogenomics in the management of advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900145-5

7 January 2021

10.1016/S1078-1439(03)00145-5

Identifiers

DOI

1 reference

9 August 2017

1 reference